Cumberland Pharmaceuticals Inc. Sustainability Profile
Cumberland Pharmaceuticals Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has established itself as a leader in the development and commercialisation of innovative therapeutics, particularly in the areas of pain management and critical care. Cumberland's core products, including Acetadote® and Vaprisol®, are distinguished by their unique formulations and targeted applications, addressing significant medical needs. With a commitment to improving patient outcomes, the company has achieved notable milestones, including successful product launches and strategic partnerships. Cumberland Pharmaceuticals continues to strengthen its market position through a focus on research and development, ensuring its offerings remain at the forefront of the healthcare landscape.
DitchCarbon Score
How does Cumberland Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cumberland Pharmaceuticals Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cumberland Pharmaceuticals Inc.'s reported carbon emissions
Cumberland Pharmaceuticals Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi). As a result, there are no significant achievements or targets to highlight regarding their carbon footprint or climate commitments. The lack of emissions data and reduction initiatives suggests that Cumberland Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy.
How Carbon Intensive is Cumberland Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is Cumberland Pharmaceuticals Inc.'s Location?
Cumberland Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cumberland Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
